{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:45:43Z","timestamp":1792741543836,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:50:44Z","timestamp":1751424644000},"page":"1013-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Autoimmune Cytopenias in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Candida","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zamprogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beha.2010.01.004","article-title":"Autoimmune complications in chronic lymphocytic leukaemia (CLL)","volume":"23","author":"Zent","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020282","article-title":"Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs","volume":"12","author":"Vitale","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.002_bib3","first-page":"1689","article-title":"Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia","volume":"91","author":"Barcellini","year":"2006","journal-title":"Haematologica (Roma)"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.002_bib4","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance","volume":"116","author":"Moreno","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.002_bib5","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features","volume":"95","author":"Mauro","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10369","article-title":"Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"74","author":"Kyasa","year":"2003","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2008.07086.x","article-title":"The prognostic significance of cytopenia in chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"141","author":"Zent","year":"2008","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.002_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428190903026492","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia\/small lymphocytic lymphoma: changes in clinical presentation and prognosis","volume":"50","author":"Zent","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2025.05.002_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2016.11.020","article-title":"Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients","volume":"72","author":"Visentin","year":"2017","journal-title":"Eur J Cancer (1990)"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.hemonc.2019.01.004","article-title":"The prevalence and prognostic significance of autoimmune cytopenias in a cohort of Egyptian patients with chronic lymphocytic leukemia","volume":"12","author":"Atef","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood-2007-09-111492","article-title":"Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia","volume":"111","author":"Visco","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.002_bib12","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2007-07-101303","article-title":"The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia","volume":"111","author":"Dearden","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3324\/haematol.2010.022079","article-title":"Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status","volume":"95","author":"Visco","year":"2010","journal-title":"Haematologica (Roma)"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-012-1663-3","article-title":"Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases","volume":"92","author":"Shvidel","year":"2013","journal-title":"Ann Hematol"},{"issue":"25","key":"10.1016\/j.hoc.2025.05.002_bib15","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood.2020008201","article-title":"Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs","volume":"137","author":"Vitale","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jcp.39.7.713","article-title":"Autoimmunity in chronic lymphocytic leukaemia","volume":"39","author":"Hamblin","year":"1986","journal-title":"J Clin Pathol"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.002_bib17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V81.10.2475.2475","article-title":"Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases","volume":"81","author":"Kipps","year":"1993","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.002_bib18","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood.V84.4.1216.1216","article-title":"High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia","volume":"84","author":"Beaume","year":"1994","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib19","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.V87.7.2615.bloodjournal8772615","article-title":"B-chronic lymphocytic leukemia: a malignancy of anti-self B cells","volume":"87","author":"Caligaris-Cappio","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib20","first-page":"80","article-title":"Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia","volume":"25","author":"Diehl","year":"1998","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","article-title":"Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment","volume":"154","author":"Hodgson","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.1993.tb03167.x","article-title":"Detection of clonal platelet antibodies in immunologically-mediated thrombocytopenias: association with circulating clonal\/oligoclonal B cells","volume":"85","author":"Christie","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2025.05.002_bib23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3389\/fonc.2019.01435","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects","volume":"9","author":"Fattizzo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.hoc.2025.05.002_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canlet.2018.04.016","article-title":"Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets","volume":"428","author":"Long","year":"2018","journal-title":"Cancer Lett"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.002_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153856","article-title":"Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia","volume":"13","author":"Vitale","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib26","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2003-10-3563","article-title":"Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells","volume":"105","author":"Hall","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib27","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.4049\/jimmunol.181.5.3674","article-title":"Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia","volume":"181","author":"Galletti","year":"2008","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/CCO.0b013e328348c683","article-title":"A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?","volume":"23","author":"Strati","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.hoc.2025.05.002_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1196\/annals.1361.044","article-title":"IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia","volume":"1051","author":"Toriani-Terenzi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.002_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semcancer.2010.09.006","article-title":"T-cell function in chronic lymphocytic leukaemia","volume":"20","author":"Riches","year":"2010","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib31","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Investig"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.002_bib32","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2007-07-101345","article-title":"Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia","volume":"111","author":"Ward","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/eci.10.96","article-title":"Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity","volume":"7","author":"Wright","year":"2011","journal-title":"Expet Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D'Arena","year":"2011","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib36","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3109\/10428194.2012.728287","article-title":"Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias","volume":"54","author":"Lad","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.002_bib37","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3109\/10428194.2014.986479","article-title":"Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias","volume":"56","author":"Lad","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V98.2.483","article-title":"Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes","volume":"98","author":"Go","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib39","article-title":"Pure red cell aplasia and lymphoproliferative disorders: an infrequent association","volume":"2012","author":"Vlachaki","year":"2012","journal-title":"Sci World J"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.002_bib40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3324\/haematol.10975","article-title":"Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells","volume":"92","author":"Grandjenette","year":"2007","journal-title":"Haematologica (Roma)"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.002_bib41","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/10428190903115410","article-title":"The role of toll-like receptors in chronic B-cell malignancies","volume":"50","author":"Muzio","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib42","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ijc.24832","article-title":"Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation","volume":"126","author":"Rozkova","year":"2010","journal-title":"Int J Cancer J Int Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.002_bib43","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3109\/10428194.2013.856426","article-title":"Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression","volume":"55","author":"Barcellini","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2025.05.002_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00005-016-0433-7","article-title":"The expression of toll-like receptors in patients with B-cell chronic lymphocytic leukemia","volume":"64","author":"Rybka","year":"2016","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.hoc.2025.05.002_bib45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2020.00367","article-title":"Role of viral and host microRNAs in immune regulation of Epstein-Barr virus-associated diseases","volume":"11","author":"Iizasa","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/jac\/dkm195","article-title":"Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"60","author":"Franchini","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.16786","article-title":"Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia","volume":"190","author":"Lopez","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.002_bib48","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00277-022-04907-7","article-title":"Hemolytic anemia in COVID-19","volume":"101","author":"Al-Kuraishy","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2025.05.002_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.791429","article-title":"Complement mediated hemolytic anemias in the COVID-19 era: case series and review of the literature","volume":"12","author":"Fattizzo","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.002_bib50","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/ajcp\/aqab210","article-title":"COVID-19 and immune-mediated RBC destruction","volume":"157","author":"Jacobs","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.16794","article-title":"Autoimmune haemolytic anaemia associated with COVID-19 infection","volume":"190","author":"Lazarian","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib52","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1111\/bjh.16883","article-title":"Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19?","volume":"190","author":"Angileri","year":"2020","journal-title":"Br J Haematol"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2025.05.002_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/10428199309054731","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine","volume":"11","author":"Di Raimondo","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2141.1995.tb05300.x","article-title":"Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia","volume":"91","author":"Myint","year":"1995","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.002_bib55","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1998.16.5.1885","article-title":"Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia","volume":"16","author":"Weiss","year":"1998","journal-title":"Journal of clinical oncology"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0609.1997.tb00933.x","article-title":"Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine)","volume":"58","author":"Robak","year":"1997","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib57","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/oxfordjournals.annonc.a059162","article-title":"Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia","volume":"6","author":"Byrd","year":"1995","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib58","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.002_bib59","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3109\/10428194.2015.1137293","article-title":"Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience","volume":"57","author":"Laurenti","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.002_bib60","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ajh.23268","article-title":"Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"87","author":"Reda","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.5","article-title":"Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study","volume":"7","author":"Montillo","year":"2017","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.002_bib63","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib64","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.002_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.002_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","author":"Stilgenbauer","year":"2018","journal-title":"Journal of clinical oncology"},{"issue":"S1","key":"10.1016\/j.hoc.2025.05.002_bib67","first-page":"1124","article-title":"Impact of venetoclax-based therapies on autoimmune cytopenias in patients with chronic lymphocytic leukemia: a multicenter study conducted by ERIC, the European Research Initiative on CLL. Presented at: EHA Congress","volume":"8","author":"Vitale","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.hoc.2025.05.002_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib69","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17474086.2023.2216930","article-title":"Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias","volume":"16","author":"Barcellini","year":"2023","journal-title":"Expet Rev Hematol"},{"issue":"25","key":"10.1016\/j.hoc.2025.05.002_bib70","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.002_bib71","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.002_bib72","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.002_bib73","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/bloodadvances.2023012541","article-title":"The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia","volume":"8","author":"Neunert","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib74","first-page":"254","article-title":"How to manage ITP with life-threatening bleeding","volume":"2023","author":"Connors","year":"2023","journal-title":"Hematology\/the Education Program of the American Society of Hematology American Society of Hematology Education Program"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib75","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood.V99.3.1092","article-title":"Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia","volume":"99","author":"Ghazal","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.002_bib76","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819031000119235","article-title":"Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases","volume":"44","author":"Zaja","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.002_bib77","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"D'Arena","year":"2006","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib78","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.17105","article-title":"Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"192","author":"Herishanu","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib79","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.23909","article-title":"Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC\/MW and GOELAMS)","volume":"90","author":"Quinquenel","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.002_bib80","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.002_bib81","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/10428190902887563","article-title":"A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia","volume":"50","author":"Kaufman","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib82","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2010.278","article-title":"Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia","volume":"25","author":"Rossignol","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.002_bib83","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/10428191003682767","article-title":"Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia\/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone","volume":"51","author":"Bowen","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib84","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1002\/ajh.25480","article-title":"Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group","volume":"94","author":"Quinquenel","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.002_bib85","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ajh.27493","article-title":"Parsaclisib for the treatment of primary autoimmune hemolytic anemia: results from a phase 2, open-label study","volume":"99","author":"Barcellini","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib86","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41375-023-01891-3","article-title":"Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias","volume":"37","author":"Nikitin","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib87","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3960\/jslrt.23023","article-title":"Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration","volume":"63","author":"Oyama","year":"2023","journal-title":"J Clin Exp Hematop"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.002_bib88","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10428194.2023.2199341","article-title":"Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report","volume":"64","author":"Allsup","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2025.05.002_bib89","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241282570","article-title":"Relapsed\/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature","volume":"15","author":"Fresa","year":"2024","journal-title":"Therapeutic advances in hematology"},{"issue":"S3","key":"10.1016\/j.hoc.2025.05.002_bib90","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000973288.67955.a3","article-title":"P1603: efficacy and safety of bruton\u2019s tyrosine kinase inhibitor zanubrutinib in ITP","volume":"7","author":"Huang","year":"2023","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.002_bib91","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-017-3039-1","article-title":"Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)","volume":"96","author":"Lacerda","year":"2017","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib92","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000202","article-title":"Refractory autoimmune cytopenias treated with venetoclax","volume":"3","author":"Gordon","year":"2019","journal-title":"HemaSphere"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.002_bib93","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3324\/haematol.2022.281850","article-title":"Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain","volume":"108","author":"Galindo-Navarro","year":"2023","journal-title":"Haematologica (Roma)"},{"key":"10.1016\/j.hoc.2025.05.002_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1260003","article-title":"Case report: successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy","volume":"13","author":"Woo","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.002_bib95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.15581","article-title":"A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia","volume":"185","author":"Paul","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib96","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.002_bib97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.27144","article-title":"Fostamatinib for warm antibody autoimmune hemolytic anemia: phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD)","volume":"99","author":"Kuter","year":"2024","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.002_bib98","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.002_bib99","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ajh.27303","article-title":"A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia","volume":"99","author":"Yan","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.002_bib100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.hoc.2025.05.002_bib101","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.002_bib102","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.002_bib103","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.2023022549","article-title":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","volume":"145","author":"Roman","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.002_bib104","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica (Roma)"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:49:27Z","timestamp":1760503767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000644"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune Cytopenias in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}